NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING
AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, April 28, 2007 - 8:30 a.m. - 12:00 p.m.
Room: CARLYLE

Chairs: Drs. Greg Cairncross and Warren Mason

8:30 a.m. Welcome and Introductions W. Mason

TRANSLATIONAL STUDIES

8:40 a.m. Canadian Brain Tumor Tissue Bank A. Guha

COMPLETED STUDIES

8:50 a.m. IND.170 – A phase I/II study of GW572016 in GBM B. Thiessen

NEW TRIALS

9:00 a.m. IND.162 – A phase I / II study of RAD001c plus Temozolomide in GBM W. Mason

9:15 a.m. CE.5-RT vs Temozolomide for low-grade glioma W. Mason D. Rheaume

9:45 a.m. CE.6-RT vs RT plus Temozolomide for elderly GBM N. Laperriere J. Perry

10:00 a.m. CEC.1 - A phase III trial of radiotherapy with and without concurrent and adjuvant temozolomide chemotherapy for 1p/19q non-deleted anaplastic gliomas W. Mason C. O’Callaghan

10:15 COFFEE BREAK

FUTURE NCIC PHASE II / III STUDIES

10:30 a.m. Proposed HUB/RTOGNCIC/EORTC trial for 1p/19q deleted anaplastic gliomas G. Cairncross

continued . . .
## Ideas for New Brain Tumour Trials

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 a.m.</td>
<td>Proposed NCIC CTG trial for newly-diagnosed GBM based on MGMT methylation status</td>
<td>J. Easaw</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>NCCTG N0574: St RT with and without WBRT for 1-3 cerebral metastases methylation status</td>
<td>C. Menard</td>
</tr>
<tr>
<td>11:15 a.m.</td>
<td>Chloroquine with radiotherapy and temozolomide for newly diagnosed GBM</td>
<td>P. Cano</td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td>Report from the NCIC CTG IND meeting</td>
<td>W. Mason</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>